Summary
The US has moved approved and licensed medical marijuana products to Schedule III. Heres what it means for research, patients, cannabis firms and markets.
Source: Ndtv
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
